This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 Safe and Sound ETF Strategies for 2H
by Sweta Killa
After a bumpy ride in the first half of the year, global stocks are bouncing back despite the trade war fears.
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.
4 Hot Sector ETFs Springing Up to Rank #1
by Sweta Killa
A number of funds in their respective sectors have seen their Ranks surging to the top hierarchy and could make great spring picks.
M&A Waves Pushing Biotech ETFs Higher
by Sweta Killa
The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.
Biotech ETFs: What Lies Ahead?
by Zacks Equity Research
It's been a good year for biotech ETFs, can the rally continue?
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
Trump Wins Healthcare Vote: ETFs to Watch
by Sweta Killa
The bill is expected to cut billions of dollars in health-care spending and result in millions of Americans going without health insurance.
Time to Buy Biotech ETFs?
by Zacks Equity Research
After a painful 2016, biotech stocks are recovering this year. What lies ahead?
What Lies Ahead for Biotech ETFs in Trump Era?
by Zacks Equity Research
Despite political risks, there are many factors supporting growth in the biotech sector.